Scott T. Aaronson, MD

Predictors of Treatment Response to Adjunctive VNS Therapy in Major Depressive Disorder: A RECOVER Trial Report

July 14, 2025

History of ECT use (lifetime and current episode) or TMS use (current episode) was prognostic of poorer outcomes across the total sample and superior benefit from active versus sham...

Scott T. Aaronson, Charles R. Conway, Charles Gordon, et al

Commentary

The Long Road Toward Equitable MDMA Treatment in the United States

May 29, 2024

Kozak and Aaronson discuss challenges in implementation of MDMA-assisted therapy, including insurance and Medicare coverage as well as cultural barriers.

Zofia Kozak, Scott T. Aaronson

Original Research

Pilot Study of High Frequency TMS for Bipolar Depression

May 20, 2024

In this study of patients with bipolar depression, 87.1% reached response and 74.2% reached remission with 6 weeks of rTMS.

Scott T. Aaronson, Eric L. Goldwaser, Paul E. Croarkin, et al

Original Research

Long-Term Safety and Efficacy of Zuranolone in MDD

December 27, 2023

Most patients with MDD achieved response after 14 days of zuranolone treatment. For patients who responded to their first treatment, the time to repeat treatment was over 4 months.

Susan G. Kornstein, Andrew J. Cutler, Scott T. Aaronson, et al

Original Research

TMS in Anxious Depression

January 11, 2023

Patients with anxious depression tend to have more severe depressive symptoms. This study examined the effects of transcranial magnetic stimulation in these patients.

Linda L. Carpenter, Harold A. Sackeim, Scott T. Aaronson, et al

Original Research

VNS Improves Quality of Life in Depression

August 21, 2018

Vagus nerve stimulation (VNS) treatment has been shown to be efficacious in treatment-resistant depression (TRD). Can VNS treatment lead to improvements in quality of life in patients with TRD...

A. John Rush, Charles R. Conway, Scott T. Aaronson, et al

Original Research

A Multisite, Naturalistic, Observational Study of Transcranial Magnetic Stimulation for Patients With Pharmacoresistant Major Depressive Disorder: Durability of Benefit Over a 1-Year Follow-Up Period

September 16, 2014

Philip G. Janicak, David L. Dunner, Linda L. Carpenter, et al

Original Research

Olanzapine Versus Divalproex Versus Placebo in the Treatment of Mild to Moderate Mania: A Randomized, 12-Week, Double-Blind Study

November 30, 2008

Jay D. Amsterdam, Mauricio Tohen, Guy M. Goodwin, et al

Predictors of Treatment Response to Adjunctive VNS Therapy in Major Depressive Disorder: A RECOVER Trial Report

The Long Road Toward Equitable MDMA Treatment in the United States

Pilot Study of High Frequency TMS for Bipolar Depression

Long-Term Safety and Efficacy of Zuranolone in MDD

TMS in Anxious Depression

VNS Improves Quality of Life in Depression

A Multisite, Naturalistic, Observational Study of Transcranial Magnetic Stimulation for Patients With Pharmacoresistant Major Depressive Disorder: Durability of Benefit Over a 1-Year Follow-Up Period

Olanzapine Versus Divalproex Versus Placebo in the Treatment of Mild to Moderate Mania: A Randomized, 12-Week, Double-Blind Study

ELSEWHERE:

FOLLOW US:

Scott T. Aaronson, MD

Predictors of Treatment Response to Adjunctive VNS Therapy in Major Depressive Disorder: A RECOVER Trial Report

The Long Road Toward Equitable MDMA Treatment in the United States

Pilot Study of High Frequency TMS for Bipolar Depression

Long-Term Safety and Efficacy of Zuranolone in MDD

TMS in Anxious Depression

VNS Improves Quality of Life in Depression

A Multisite, Naturalistic, Observational Study of Transcranial Magnetic Stimulation for Patients With Pharmacoresistant Major Depressive Disorder: Durability of Benefit Over a 1-Year Follow-Up Period

Olanzapine Versus Divalproex Versus Placebo in the Treatment of Mild to Moderate Mania: A Randomized, 12-Week, Double-Blind Study

Watch the New PsychCase360

Subscribe to readmore articles

Subscribe to read
more articles